Naslov
Oral JAK inhibitors for atopic dermatitis - experience from the Clinical Hospital Center Rijeka

Autori
Grković, Marija ; Dujmović-Hasanbegović, Katarina ; Prpić Massari, Larisa ; Peternel, Sandra

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
2nd Symposium of the International Contact Dermatitis Research Group - abstract book / - , 2023

Skup
2nd Symposium of the International Contact Dermatitis Research Group

Mjesto i datum
Split, Hrvatska, 31.03.2023. - 02.04.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
atopic dermatitis ; baricitinib ; upadacitinib

Sažetak
Introduction: Baricitinib, an oral selective JAK1/JAK2 inhibitor, was approved by the Croatian Health Insurance Fund for the treatment of adult patients with severe AD in October 2021, and upadacitinib, a selective JAK1 inhibitor, gained approval for adolescents and adults in April 2022. We aim to assess the overall outcomes with the use of these drugs in AD patients treated at the Clinical Hospital Center Rijeka (CHCR) until February 2023. Materials and methods: Clinical and laboratory parameters of patients with AD treated with baricitinib or upadacitinib in the period from approvals until February 2023 at the CHCR were reviewed. Disease severity was assessed by the SCORAD index. Results: In the examined period, 10 patients were prescribed baricitinib. Mean SCORAD score at baseline was 62.2. At 8 weeks, 9 out of 10 patients achieved a reduction of at least 50% (or better) in SCORAD ; one patient that did not achieve it reported irregular usage of medication, but achieved it after additonal 4 weeks. Two patients experienced early loss of efficacy at 12 weeks and were therefore switched to upadacitinib. All of the remaining 8 patients, treated for a period of 5-15 months, have sustained disease control, with only occasional mild recurrences that resolve upon treatment with emollients or mid-potency topical corticosteroids. Several patients developed mild side effects which did not require discontinuation of therapy: one had asymptomatic microhematuria, another one had mild acne and 2 patients reported dyspeptic symptoms. One patient presented with an elevation in platelet count (515x109/L), and 6 patients had asymptomatic increases of creatine kinase levels. Five patients had an increase in cholesterol and one patient had transient increase in triglycerides. Six patients were prescribed upadacitinib, but it has been used for at least 12 weeks in only 3 patients, all of which experienced at least 50% improvement in SCORAD. Two of the patients experienced worsening of acne, and there was mild neutropenia in 2 patients. Conclusion: Based on the rapid and maintained clinical improvement observed in the majority of our patients and the lack of significant side effects, the experience gathered so far supports further use of JAK inhibitors as highly efficient and well-tolerated therapeutic options for patients with severe AD.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA